Prostatis Group’s Vanguard Short-Term Corporate Bond ETF VCSH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-12,280
Closed -$164K 235
2023
Q2
$164K Buy
+12,280
New +$933K 0.08% 115
2022
Q3
Sell
-3,568
Closed -$272K 72
2022
Q2
$272K Sell
3,568
-301
-8% -$23.1K 0.42% 31
2022
Q1
$302K Sell
3,869
-4,869
-56% -$387K 0.24% 58
2021
Q4
$710K Sell
8,738
-1,647
-16% -$135K 0.44% 40
2021
Q3
$856K Sell
10,385
-1,440
-12% -$119K 0.51% 44
2021
Q2
$978K Buy
11,825
+2,683
+29% +$222K 0.67% 40
2021
Q1
$754K Buy
+9,142
New +$757K 0.59% 37

Other funds holding VCSH

Prostatis Group's VCSH Position: Q3 2023 in Review

Prostatis Group sold out of Vanguard Short-Term Corporate Bond ETF (VCSH) in Q3 2023, closing a stake of 12,280 shares — an estimated $164K sold.

Prostatis Group first reported a position in VCSH in Q1 2021 and held it in 7 quarters. The position peaked at $978K in Q2 2021. 1,214 funds tracked by Wall St. Rank hold VCSH as of Q3 2023.

  • Prostatis Group reported no remaining Vanguard Short-Term Corporate Bond ETF position as of Q3 2023 after selling out during the quarter.
  • Prostatis Group sold 12,280 Vanguard Short-Term Corporate Bond ETF shares in Q3 2023, an estimated $164K.
  • Prostatis Group first reported a position in Vanguard Short-Term Corporate Bond ETF in Q1 2021 and held it in 7 quarters.
  • Prostatis Group's Vanguard Short-Term Corporate Bond ETF position peaked at $978K in Q2 2021.
  • 1,214 funds tracked by Wall St. Rank held Vanguard Short-Term Corporate Bond ETF as of Q3 2023.

Based on Prostatis Group's 13F filing for Q3 2023, filed 21 Mar 2025.